RT Book, Section
A1 Keen, Brendan
A1 Sherman, Marian
A2 Freeman, Brian S.
A2 Berger, Jeffrey S.
SR Print(0)
ID 1135739028
T1 Anti-Parkinson Drugs
T2 Anesthesiology Core Review: Part Two Advanced Exam
YR 2016
FD 2016
PB McGraw-Hill Education
PP New York, NY
SN 9781259641770
LK accessanesthesiology.mhmedical.com/content.aspx?aid=1135739028
RD 2024/04/19
AB Parkinson's  disease  (PD)  affects  3%  of  the  population  older  than  66  years  of  age;  therefore,  PD  is  encountered  relatively  commonly  in  clinical  anesthesia  practice.  Symptoms  include  resting  tremor,  rigidity,  akinesia,  and  postural  instability.  These  symptoms  are  due  to  destruction  of  dopaminergic  neurons  in  the  substania  nigra,  a  component  of  the  basal  ganglia.  The  basal  ganglia  relays  motor  signals  from  cortex  to  thalamus  and  brainstem  nuclei.  Loss  of  dopaminergic  neurons  increasingly  activates  basal  ganglia  inhibitory  nuclei,  thereby  suppressing  cortical  motor  signals  and  inhibiting  brainstem  locomotor  areas.  Such  disturbances  in  signaling  produce  Parkinsonian  symptoms.  Pharmacologic  agents  treat  PD  symptoms,  mostly  through  dopaminergic  pathways.